Checkpoint inhibitors such as anti-PD-1 (programmed death 1), anti-PD-L1 (programmed death ligand 1), or anti-CTLA-4 (cytotoxic T lymphocyte antigen 4) antibodies are widely used in cancer immunotherapy [1,2,3,4]. This evidence concerns the gene CD274 and cancer.